RDY
Dr. Reddy'S Laboratories·NYSE
--
--(--)
--
--(--)
RDY fundamentals
Dr. Reddy'S Laboratories (RDY) Revenue Breakdown: Q3 2026 Business & Regional Performance
Dr. Reddy'S Laboratories (RDY) reported total revenue of 971.37M USD in Q3 2026, with its core business segment Global Generics contributing 90.66%. Regionally, United States remained the largest market, accounting for 34.94% of total revenue. Explore Dr. Reddy'S Laboratories's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
Dr. Reddy'S Laboratories (RDY) reported total revenue of 971.37M USD in Q3 2026, with its core business segment Global Generics contributing 90.66%. Regionally, United States remained the largest market, accounting for 34.94% of total revenue. Explore Dr. Reddy'S Laboratories's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What factors drove the changes in Dr. Reddy'S Laboratories's revenue and profit?What were the key takeaways from Dr. Reddy'S Laboratories’s earnings call?What is the revenue and EPS growth rate for Dr. Reddy'S Laboratories year over year?Did Dr. Reddy'S Laboratories beat or miss consensus estimates last quarter?What is Dr. Reddy'S Laboratories's latest dividend and current dividend yield?What does Dr. Reddy'S Laboratories do and what are its main business segments?What is Dr. Reddy'S Laboratories's gross profit margin?What guidance did Dr. Reddy'S Laboratories's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
